

1 **Robust metabolomic age prediction based on a wide selection of metabolites**

2 Tariq Faquih¹, Astrid van Hylckama Vlieg¹, Praveen Surendran^{2,3,4,5,6}, Adam S. Butterworth^{2,3,4,7,8},
3 Ruifang Li-Gao^{1,9}, Renée de Mutsert¹, Frits R. Rosendaal¹, Raymond Noordam¹⁰, Diana van Heemst¹⁰,
4 Ko Willems van Dijk^{11,12,13}, Dennis O. Mook-Kanamori^{1,14}

5
6 ¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
7 (T.O.F.; A.v.H.V.; R.L.-G.; R.d.M; F.R.R.; D.O.M.-K.)

8
9 ² British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary
10 Care, University of Cambridge, Cambridge, UK. (P.S.; A.S.B.)

11
12 ³ British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK.
13 (P.S.; A.S.B.)

14
15 ⁴ Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
16 Cambridge, UK. (P.S.; A.S.B.)

17
18 ⁵ Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge,
19 Cambridge, UK. (P.S.)

20
21 ⁶ GSK plc., Stevenage, England, United Kingdom; (P.S.)

22
23 ⁷ Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK;
24 (A.S.B.)

25
26 ⁸ NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, Department of Public
27 Health and Primary Care, University of Cambridge, Cambridge, UK. (A.S.B.)

28
29 ⁹ Metabolon, Inc., Morrisville, North Carolina, United State of America. (R.L.-G.)

30
31 ¹⁰ Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical
32 Center, Leiden, The Netherlands. (R.N.; D.v.H.)

33
34 ¹¹ Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
35 (K.W.v.D)

36
37 ¹² Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center,
38 Leiden, The Netherlands. (K.W.v.D)

39
40 ¹³ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center,
41 Leiden, The Netherlands. (K.W.v.D)

42
43 ¹⁴ Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The
44 Netherlands. (D.O.M.-K.)

45 **Abstract**

46 Chronological age is a major risk factor for numerous diseases. However, chronological age does not
47 capture the complex biological aging process. Biological aging can occur at a different pace in
48 individuals of the same chronological age. Therefore, the difference between the chronological age
49 and biologically driven aging could be more informative in reflecting health status. Metabolite levels
50 are thought to reflect the integrated effects of both genetic and environmental factors on the rate of
51 aging, and may thus provide a stronger signature for biological age than those previously developed
52 using methylation and proteomics. Here, we set out to develop a metabolomic age prediction model
53 by applying ridge regression and bootstrapping with 826 metabolites (of which 678 endogenous and
54 148 xenobiotics) measured by an untargeted high-performance liquid chromatography mass
55 spectrometry platform (Metabolon) in 11,977 individuals (50.2% men) from the INTERVAL study
56 (Cambridge, UK). Participants of the INTERVAL study are relatively healthy blood donors aged 18-75
57 years. After internal validation using bootstrapping, the models demonstrated high performance with
58 an adjusted R^2 of 0.82 using the endogenous metabolites only and an adjusted R^2 of 0.83 when using
59 the full set of 826 metabolites with age as outcome. The latter model performance could be indicative
60 of xenobiotics predicting frailty. In summary, we developed robust models for predicting metabolomic
61 age in a large relatively healthy population with a wide age range.

62 **Introduction**

63 Chronological age is a major risk factor for a multitude of diseases (1, 2). The biology of aging
64 comprises complex and multifactorial processes that are influenced by genetic, lifestyle and
65 environmental factors (3-5). Evidently, the rate of biological aging varies between individuals, as in
66 contrast to other individuals of the same age group, wherein, some individuals are able to live to an
67 older chronological age without age-related diseases and disability (3). This suggests that
68 chronological age does not align with the biological aging process. For this reason, several studies have
69 aimed to capture the signature of biological changes due to aging process by predicting its rate based
70 on biological factors using, for example, DNA methylation (6) and proteins (7).

71 Metabolomic profiling aims to identify small molecules that are mostly substrates or products of
72 metabolism (metabolites). The number of metabolomics studies has increased in recent years due to
73 major technological advances and the availability of (validated and high throughput) commercial and
74 noncommercial analyses platforms. In addition, the current platforms have improved their capability
75 to detect and quantify large numbers of endogenous and xenobiotic metabolites(8, 9). Since individual
76 metabolomic profiles reflect the influences of both genetic and acquired factors, they are thought to
77 provide a more holistic representation of biological processes, such as aging (8, 9). Furthermore, as

78 metabolomic profiles are strongly affected by chronological age (4, 10) and sex (11, 12), they have
79 been used to develop prediction models of chronological age (i.e., the metabolomic age) (13-16).
80 However, predicting metabolomic age using metabolomics had limited success or faced
81 methodological limitations due to several reasons. First, some studies used a relatively small sample
82 size to predict age using hundreds or even thousands of metabolite predictors (10, 17). The inclusion
83 of a larger number of predictors than the number of samples may cause overfitting and bias. Second,
84 previous metabolomic age studies used targeted platforms, such as the Nightingale platform, that
85 specifically measure a small number of lipoproteins and some low-molecular metabolites. This limits
86 the variety of the metabolites and the information used for the prediction of age. Third, studies may
87 be limited by the age distribution of the cohort study. This may restrict the model to a specific age
88 range which affects the generalizability of the model in other studies and other age groups (10).
89 Fourth, generalizability may also be reduced if the model is developed in cohorts with an oversampling
90 of individuals with specific disease outcomes or specific population characteristics (7, 13). Fifth,
91 statistical methodology such as stepwise selection, have been reported to cause overfitting of the
92 prediction model (18). Finally, it is challenging to examine the model's validity and generalizability in
93 external studies or different populations particularly due to the dynamic nature of metabolite levels
94 (19-21).

95 In this study, we aimed to develop a model to predict metabolomic age in a large healthy population
96 with a widespread age range, using a single untargeted metabolomics platform. To attain this goal,
97 we developed a prediction model using data from the INTERVAL study (22) (University of Cambridge,
98 Cambridge, UK). Metabolomic profiles were available in 11,977 participants as measured using
99 Metabolon's (Durham, North Carolina, USA) untargeted metabolomics platform. These
100 measurements included a broad range of endogenous and xenobiotic metabolites (n=1,363) from
101 various biochemical pathways, thereby enabling the capture of metabolites related to a vast range of
102 ageing effects.

103 **Methods**

104 **INTERVAL Study**

105 The INTERVAL study is a prospective cohort study of approximately 50,000 participants nested within
106 a pragmatic randomized sample of blood donors (22). Between 2012 and 2014, blood donors, aged
107 18 years and older, were consented and recruited from 25 National Health Service Blood and
108 Transplant (NHSBT) static donor centers across the UK. The INTERVAL study was approved by The
109 National Research Ethics Service (11/EE/0538). Individuals with major disease (myocardial infarction,

110 stroke, cancer etc.) as well as those who reported being unwell or having had recent illness or infection
111 or did not fulfill the other criteria required for blood donation (22, 23) were ineligible for the study.
112 Therefore, participants included in the study were predominantly healthy. Participants completed
113 online questionnaires addressing basic lifestyle and health-related information, including self-
114 reported height and weight, ethnicity, smoking status, alcohol consumption, doctor-diagnosed
115 anemia, use of medications (hormone replacement therapy, iron supplements) and menopausal
116 status (22). Untargeted metabolomic data were available in 11,979 individuals (age range 18 - 75).
117 Two individuals had incorrect or missing height/weight values and were therefore excluded from the
118 study. Thus, the final sample size for the current study was 11,977.

119 **Untargeted metabolomic measurements**

120 Untargeted metabolomic measurements were quantified at Metabolon Inc. (Durham, North Carolina,
121 USA) using Metabolon™ Discovery HD4 platform. In brief, this process involves four independent ultra-
122 high-performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (24, 25). Of
123 these platforms, two used positive ionization reverse phase chromatography, one used negative
124 ionization reverse phase chromatography, and one used hydrophilic interaction liquid
125 chromatography negative ionization (25). Known metabolites were annotated at Metabolon Inc. with
126 chemical names, super pathways, sub pathways, biochemical properties, and compound identifiers
127 from various metabolite databases. Metabolomic measurements in the INTERVAL study were
128 conducted in three batches (n=4087, 4566, and 3326). Subsequent harmonization and quality checks
129 were performed between the batches by Metabolon. All metabolite measurements were scaled to a
130 median of 1.

131 **Selection of Predictors**

132 We aimed to select metabolites consistently and reliably measured by the Metabolon platform. In
133 total 1,411 metabolites were measured in the INTERVAL study. First, we removed metabolites
134 completely missing in at least one of the batches (n=175). Second, we excluded metabolites without
135 annotation (unnamed metabolites) (n=258), keeping only endogenous and xenobiotic metabolites.
136 These metabolites were excluded as they are inconsistently measured by the platform and are highly
137 variable between batches and studies. Moreover, the lack of full annotation increases the uncertainty
138 that we are using the same metabolite across batches and studies and leaves no secondary
139 information for further verification. Third, we excluded metabolites measured in less than 100
140 individuals (n=30). Fourth, to ensure that the metabolites that are used for our model are not unique
141 for the INTERVAL study, we cross-referenced our dataset with an independent study with Metabolon

142 measurements. For this we used the Netherlands Epidemiology of Obesity (NEO) study, a population-
143 based (n=599) cohort study of individuals aged 45–65 years (26, 27). Based on this comparison, we
144 additionally excluded 122 metabolites that were not detected in the NEO study. The final set of
145 metabolites included 826 metabolites, with 678 endogenous and 148 xenobiotic metabolites that
146 were confirmed to be regularly measured by the Metabolon platform (Figure 1).

147 **Missing value imputation**

148 Missing values were imputed using the pipeline as described in our previous work (27). In brief,
149 endogenous metabolites were imputed by multiple imputation using chained equations method to
150 generate five imputed datasets (m=5). For each metabolite with missing values, we used the outcome
151 variable (i.e., age), 5-10 highly correlated related metabolites, body mass index (BMI), center number
152 where the blood samples were collected, and the batch number to impute the missing values.
153 Xenobiotic metabolites were imputed to zero to account for true missingness.

154 **Model Development**

155 For the development of the model, we used ridge regression (28) to reduce potential overfitting. Cross
156 validation was performed (n=10) in each imputed dataset to calculate the optimal shrinkage term
157 (λ). Subsequently the mean of the λ values was used to develop the model on the stacked
158 imputed datasets (i.e., all 5 datasets combined as one). Accordingly, the weight of the observations in
159 the stacked dataset was set to $1/m = 1/5 = 0.2$ (20). As the outcome (age) is a continuous variable, we
160 assessed the fit of the model by deriving the R^2 . As an additional sensitivity test, we used generalized
161 additive model (GAM) to examine and calculate the R^2 for the nonlinear correlation. Internal validation
162 was performed using bootstrapping (b=100). Bootstrapping results were used for the optimization of
163 R^2 and the calculation of the mean squared error (MSE) and the mean absolute error (MAE) of the
164 model. Two models were developed using two sets of the selected metabolite predictors. First, we
165 used the full set of endogenous and xenobiotic metabolites (n=826) to develop “model A”. Second,
166 we used only the endogenous metabolites (n=678) to develop “model B”. As previous studies found
167 that metabolomic profiles (12, 29) and aging (30-32) are influenced by the sex of individuals, we
168 included sex as an additional predictor in both models.

169 **Sample size considerations**

170 The primary database used to create the prediction model was the INTERVAL study (n= 11,977) with
171 826 predictors. We used the formulas described by Riley et al. (33) to confirm that our sample size (n)
172 and number of predictor (p) are sufficient to minimize overfitting and provide high prediction
173 precision. First, we calculated Copas global shrinkage factor for our data (34, 35) to see if it is above

174 the recommended 0.9 threshold (33). Based on this calculation the estimated shrinkage factor was
175 0.95 if the adjusted R^2 of the model was assumed to be 0.7. Second, we calculated the sample size
176 required to ensure a small difference between the R^2 and the adjusted R^2 for the development model.
177 Assuming the adjusted R^2 was 0.7 again and a small desired R^2 difference ($R^2_{diff}=0.025$), then the
178 sample size required to achieve this should be at least $n=9913$. Third, we checked the sample size
179 required for precise residual standard deviation of the model. Accordingly, we found the multiplicative
180 margin of error (MMOE) to be less than 10% (MMOE =1.3%) using our n and p in the INTERVAL study.
181 Finally, we checked the precision of the mean predicted outcome value (predicted age) of the model.
182 We used n and p for the INTERVAL study and assumed that predicted age would have a mean of 45
183 and a variance of 35. Accordingly, the upper and lower bounds were approximately 45.34 and 44.65
184 respectively. Thus, the MMOE for the mean predicted outcome was less 1% (MMOE= $45.34 / 45 =$
185 $1.007 = 0.7\%$). Therefore, the sample size of the INTERVAL study was optimal to minimize overfitting,
186 optimism, and provide a precise estimation of the residual standard deviation and mean predicted
187 values.

188 Results

189 Population characteristics

190 Characteristics of the total INTERVAL study population and age subgroups are summarized in Table 1.
191 In total 11,977 individuals were included and had a normal age distribution with a mean age of 45
192 years and a range of 18 – 75 years. The number of men and women was approximately equal (50.2%
193 were men). BMI was largely in the recommended range of 18.5-24.9 kg/m² (36) with a mean BMI of
194 22.8 kg/m² and was similar in all age groups.

195


	Total	18 to 25	25 to 35	35 to 45	45 to 55	55 to 65	65 to 75
N	11977	1178	2245	2152	2867	2602	811
Age (years), mean (range)	45 (18-75)						
Men, n (%)	6019 (50.2%)	485 (41.2%)	965 (42.3%)	1042 (48.4%)	1560 (54.4%)	1480 (56.9%)	546 (67.3%)
BMI (kg/m ²), mean (SD)	22.8 (4.2)	21.3 (4.0)	22.0 (4.2)	23.3 (4.4)	23.5 (4.3)	23.0 (3.9)	22.6 (3.5)

196 Table 1. Characteristics of the INTERVAL study population.

197 Metabolomic Age Prediction

198 Prediction models A (endogenous plus xenobiotic metabolites) and B (endogenous metabolites only)
199 were developed in the INTERVAL study using ridge regression. The workflow including metabolite
200 selection, missing value imputation, and analyses are summarized in Figure 1. Internal validation using
201 bootstrapping (resampling n = 100) and optimization provided an R² of 0.83 (MSE=31, MAE=4.4) for
202 model A, and 0.82 (MSE=33.7, MAE=4.6) for model B. The R² for the generalized additional model
203 (GAM) were slightly higher for both models, 0.85 for model A and 0.84 for model B (Figure 2,
204 Supplementary Table 1, Supplementary Figure 1). Full tables with the intercept, sex and metabolite
205 coefficients for model A and B are provided in Supplementary Table 2. This table also contains the
206 mean values for the metabolites from the INTERVAL study.

207




208

209

210

Figure 1: Flowchart of the selection of predictor metabolites and the development steps for the metabolomic age prediction model in the INTERVAL study



211

212 Figure 2: Correlation plots of the Metabolomic age (predicted age) on the horizontal axis and the
213 chronological age on the vertical axis for model A (A) and model B (B). The data used is the stacked
214 imputed datasets in the INTERVAL study. Abbreviations: GAM, generalized additive model.

215 Discussion

216 In this study, we developed a prediction model for metabolomic age based on metabolite
217 measurements, including a wide range of endogenous and xenobiotic metabolites belonging to a
218 variety of biochemical pathways. The metabolomic measurements were performed in a single study
219 using the same metabolomic platform and harmonized for within study and between batch variation.
220 Importantly, we used multiple imputation, ridge regression, and bootstrapping (20) to develop and
221 internally validate the metabolomic age prediction models. We developed two models, with the first
222 model A using both endogenous and xenobiotic metabolites (n=826), and the second model B using
223 the endogenous metabolites only (n=678). Both models had high adjusted R^2 (model A = 0.83; Model
224 B = 0.82), however, model B had slightly higher MSE and MAE, indicating higher error for the predicted
225 values.

226 Ridge Regression for Metabolomic Age

227 Our metabolomic age model is based on ridge regression which generates shrinkage factors that
228 shrink metabolite coefficients with weak influence on the model to small values. Unlike methods such
229 as LASSO and elastic net regression, this shrinkage never causes the coefficients to reach zero.
230 Therefore, unlike those methods, ridge regression does not perform selection of predictors, in this
231 case metabolites, due to the shrinkage term. Thus, the model consistently includes the same
232 metabolites during the cross validation and internal validation by bootstrapping (20). Ridge regression

233 thus ensures rigorousness and consideration of all the selected metabolite predictors. In addition, we
234 found in our model that nonlinear GAM R^2 to be slightly higher than linear R^2 in both models. Figure 2
235 also shows that the GAM line curves at the edges of the age ranges. Therefore, predicting
236 metabolomic age from this model in a nonlinear form, by adding a quadratic term or using a spline
237 function, may further expand the model flexibility.

238 **Strengths and Limitations**

239 A major strength of our current study is the development of robust metabolomic age prediction
240 models based on a large number of metabolites measured in a large cohort with a wide age
241 distribution. This sample size was confirmed to fit the required criteria for developing a model with
242 low overfitting (33). Furthermore, the INTERVAL study included relatively healthy blood donors as
243 participants. Blood donors are prescreened for a number of common diseases, making it a suitable
244 study to develop a metabolomic age without being affected by specific disease-related effects on
245 metabolites. Unlike previous metabolomic age predictors (alternatively referred to as metabolomic
246 “clocks”), we developed our model using the latest Metabolon metabolomics platform that measures
247 a large selection of metabolites. An advantage of this platform is the inclusion of xenobiotics, such as
248 those derived from medication or pollution as well as endogenous metabolites. Thus, we were able to
249 include metabolites originating from various internal and external sources. The xenobiotic metabolites
250 represent some of the acquired environmental and lifestyle exposures of individuals that could play a
251 role in biological aging. For example, medication metabolites could be a predictor of frailty. However,
252 our study has two limitations. First, because the INTERVAL study does not have data for health-related
253 outcomes, we could not assess the effects of different disease outcomes and health phenotypes on
254 the metabolomic age. Second, as the INTERVAL study used here was cross sectional, we could not
255 examine the model overtime or examine the ability of metabolomic age to predict disease outcomes
256 or mortality in a future time point.

257 **External Validation for Metabolomic Age and Future Applications**

258 Prediction models may suffer from overfitting due to selection bias, small sample size, methodology
259 limitations, and lack of internal validation and calibration during development. However, another
260 common issue regarding prediction modelling, such as the case with metabolomic age, is the challenge
261 to externally validate them. This a common issue with prediction models in general. Indeed, few
262 studies perform external validation of prediction models (19, 37). The reasons for the lack of external
263 validation include the difficulty of applying and reproducing the prediction model method, lack of the
264 full prediction variables to develop the model in the new dataset, or a lack of an appropriate sample

265 size for external validation. Without external validation, the quality of the models cannot be properly
266 assessed, and a model could still be overfitted despite presenting good results during internal
267 validation(20, 21, 38). We took advantage of the sample size and wide age range to use a stringent
268 ridge regression and internal validation method to develop the metabolomic age model. The resulting
269 model demonstrated a high R^2 for the metabolomic age. The high R^2 from our models is unlikely to be
270 due be overfitting as we considered and calculated the power and sensitivity of the model based on
271 the sample size and number predictors (33), in addition to the rigorous prediction modelling
272 methodology. The metabolomic age was able to predict chronological age well but not perfectly. The
273 missing 0.2 from R^2 is likely a reflection the biological aging process captured by the metabolomic age.
274 However, future robust external validation, using weak and moderate calibrations in other
275 populations (38) would be valuable for the metabolomic age models presented in this paper.

276 Several age prediction models have been developed that utilize different biological measurements
277 such as targeted metabolomics (7, 14), proteomics (7), and epigenetics (DNA methylation)(6). These
278 studies have reported that the metabolites were a strong predictor of body mass index, metabolic
279 syndrome, cancer (7), type 2 diabetes, and cardiovascular disease (14). Furthermore, other biological
280 clocks using proteomics and epigenetics were reported to be associated with depression and other
281 outcomes (7). Therefore, it will be valuable to apply the prediction models presented in this paper in
282 large longitudinal cohorts and examine the metabolomic age in relation to calendar age with the
283 aforementioned phenotypes and other health related outcomes. Assessing the association between
284 the residual between the chronological and metabolomic age with disease and health phenotypes
285 overtime will provide clinically relevant prediction. The prediction strength will indicate the
286 robustness of our model and provide the means to for external validation and re-calibration of the
287 model.

288 In addition to our aim of addressing primary issues of the development of metabolomic age models,
289 the Metabolon platform is expanded on the range of metabolites that can potentially be a better
290 predictor of age. For example, previous metabolomic age studies have not measured or included
291 xenobiotic metabolites. In our study, we were able to include this additional group of metabolites in
292 model A. Furthermore, Model A may also be used in tandem with metabolomic age from targeted
293 platforms, and biological clocks of different biological molecules measurements, similar to the work
294 by Jansen et al. (7), to possibly improve or compare their predictive performance and their ability of
295 capturing the effects of health-related phenotypes.

296 **Conclusions**

297 We developed metabolomic age prediction models in a large relatively healthy population using a
298 wide array of endogenous and xenobiotic metabolites. In model A with the endogenous and
299 xenobiotic metabolites and in model B with endogenous metabolites only, the R^2 of the linear fit was
300 0.82 and 0.83, respectively. We provided the full list of metabolites and their coefficients for both
301 models. This data can enable other researchers to replicate our metabolomic age prediction model,
302 externally validate it in their own studies with different disease outcomes and combine them with
303 other age prediction models.

304 References

- 305 1. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. *Circ Res.*
306 2012;110(8):1097-108. doi:10.1161/CIRCRESAHA.111.246876
- 307 2. Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the role of
308 concussive and subconcussive impacts. 2012;40(3):138.
- 309 3. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.*
310 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039
- 311 4. Hoffman JM, Lyu Y, Pletcher SD, Promislow DEL. Proteomics and metabolomics in ageing
312 research: from biomarkers to systems biology. *Essays Biochem.* 2017;61(3):379-88.
313 doi:10.1042/EBC20160083
- 314 5. Brooks-Wilson AR. Genetics of healthy aging and longevity. 2013;132(12):1323-38.
- 315 6. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biology.*
316 2013;14(10):3156. doi:10.1186/gb-2013-14-10-r115
- 317 7. Jansen R, Han LK, Verhoeven JE, et al. An integrative study of five biological clocks in somatic
318 and mental health. *Elife.* 2021;10. doi:10.7554/eLife.59479
- 319 8. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art
320 in 2015. *Front Bioeng Biotechnol.* 2015;3:23. doi:10.3389/fbioe.2015.00023
- 321 9. Rattray NJW, Deziel NC, Wallach JD, et al. Beyond genomics: understanding exposotypes
322 through metabolomics. *Hum Genomics.* 2018;12(1):4. doi:10.1186/s40246-018-0134-x
- 323 10. Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. *Nature Reviews*
324 *Genetics.* 2022. doi:10.1038/s41576-022-00511-7
- 325 11. Martin FJ, Montoliu I, Kussmann M. Metabonomics of ageing - Towards understanding
326 metabolism of a long and healthy life. *Mech Ageing Dev.* 2017;165(Pt B):171-9.
327 doi:10.1016/j.mad.2016.12.009
- 328 12. Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. *Aging*
329 *Cell.* 2012;11(6):960-7. doi:10.1111/j.1474-9726.2012.00865.x
- 330 13. Macdonald-Dunlop E, Taba N, Klarić L, et al. A catalogue of omics biological ageing clocks
331 reveals substantial commonality and associations with disease risk. *Aging.* 2022;14(2):623-59.
332 doi:10.18632/aging.203847
- 333 14. van den Akker EB, Trompet S, Barkey Wolf JJH, et al. Metabolic Age Based on the BBMRI-NL
334 (1)H-NMR Metabolomics Repository as Biomarker of Age-related Disease. *Circulation. Genomic and*
335 *precision medicine.* 2020;13(5):541-7. doi:10.1161/circgen.119.002610
- 336 15. Hertel J, Friedrich N, Wittfeld K, et al. Measuring Biological Age via Metabonomics: The
337 Metabolic Age Score. *J Proteome Res.* 2016;15(2):400-10. doi:10.1021/acs.jproteome.5b00561
- 338 16. Rist MJ, Roth A, Frommherz L, et al. Metabolite patterns predicting sex and age in
339 participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. *PLoS One.*
340 2017;12(8):e0183228. doi:10.1371/journal.pone.0183228
- 341 17. Hwangbo N, Zhang X, Raftery D, et al. A Metabolomic Aging Clock Using Human
342 Cerebrospinal Fluid. *The Journals of Gerontology: Series A.* 2021;77(4):744-54.
343 doi:10.1093/gerona/glab212 %J The Journals of Gerontology: Series A
- 344 18. Smith G. Step away from stepwise. *Journal of Big Data.* 2018;5(1):32. doi:10.1186/s40537-
345 018-0143-6
- 346 19. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic
347 models: what, why, how, when and where? *Clinical Kidney Journal.* 2020;14(1):49-58.
348 doi:10.1093/ckj/sfaa188 %J Clinical Kidney Journal
- 349 20. Steyerberg EW. *Clinical Prediction Models.* 2nd ed. Cham, Switzerland: Springer
350 International Publishing; 2019.
- 351 21. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction
352 research:: A clinical example. *Journal of Clinical Epidemiology.* 2003;56(9):826-32.
353 doi:[https://doi.org/10.1016/S0895-4356\(03\)00207-5](https://doi.org/10.1016/S0895-4356(03)00207-5)

- 354 22. Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals
355 between blood donations can be safely and acceptably decreased to optimise blood supply: study
356 protocol for a randomised controlled trial. *Trials*. 2014;15:363-. doi:10.1186/1745-6215-15-363
357 23. NHS Blood Donation Who can give blood. 2022. [https://www.blood.co.uk/who-can-give-](https://www.blood.co.uk/who-can-give-blood)
358 [blood](https://www.blood.co.uk/who-can-give-blood).
359 24. Evans A, Bridgewater B, Liu Q, et al. High resolution mass spectrometry improves data
360 quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput
361 profiling metabolomics. 2014;4(2):1.
362 25. Rhee EP, Waikar SS, Rebholz CM, et al. Variability of Two Metabolomic Platforms in CKD.
363 *Clinical Journal of the American Society of Nephrology*. 2019;14(1):40. doi:10.2215/CJN.07070618
364 26. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity
365 (NEO) study: study design and data collection. *Eur J Epidemiol*. 2013;28(6):513-23.
366 doi:10.1007/s10654-013-9801-3
367 27. Faquih T, van Smeden M, Luo J, et al. A Workflow for Missing Values Imputation of
368 Untargeted Metabolomics Data. *Metabolites*. 2020;10(12). doi:10.3390/metabo10120486
369 28. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal Problems.
370 *Technometrics*. 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634
371 29. Saner C, Harcourt BE, Pandey A, et al. Sex and puberty-related differences in metabolomic
372 profiles associated with adiposity measures in youth with obesity. *Metabolomics*. 2019;15(5):75.
373 doi:10.1007/s11306-019-1537-y
374 30. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. *eLife*.
375 2021;10:e63425. doi:10.7554/eLife.63425
376 31. Nakamura E, Miyao K, JoGSABS, Sciences M. Sex differences in human biological aging.
377 2008;63(9):936-44.
378 32. McCrory C, Fiorito G, McLoughlin S, et al. Epigenetic clocks and allostatic load reveal
379 potential sex-specific drivers of biological aging. 2020;75(3):495-503.
380 33. Riley RD, Snell KIE, Ensor J, et al. Minimum sample size for developing a multivariable
381 prediction model: Part I - Continuous outcomes. *Statistics in medicine*. 2019;38(7):1262-75.
382 doi:10.1002/sim.7993
383 34. Copas JB. Regression, prediction and shrinkage. *Journal of the Royal Statistical Society: Series*
384 *B*. 1983;45(3):311-35.
385 35. Copas JB. Using regression models for prediction: shrinkage and regression to the mean.
386 *Statistical methods in medical research*. 1997;6(2):167-83. doi:10.1177/096228029700600206
387 36. WHO WHO. A healthy lifestyle - WHO recommendations. World Health Organization: WHO.
388 2010.
389 37. Siontis GCM, Tzoulaki I, Castaldi PJ, Ioannidis JPA. External validation of new risk prediction
390 models is infrequent and reveals worse prognostic discrimination. *Journal of Clinical Epidemiology*.
391 2015;68(1):25-34. doi:<https://doi.org/10.1016/j.jclinepi.2014.09.007>
392 38. Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive
393 analytics. *BMC Medicine*. 2019;17(1):230. doi:10.1186/s12916-019-1466-7

394

395

396 Funding

397 The INTERVAL study was funded by NHSBT and the NIHR Blood and Transplant Research Unit in
398 Donor Health and Genomics (NIHR BTRU-2014-10024). The trial's coordinating centre at the
399 Department of Public Health and Primary Care at the University of Cambridge, Cambridge, UK, has
400 received core support from the UK Medical Research Council (G0800270), British Heart Foundation
401 (SP/09/002), and the NIHR Cambridge Biomedical Research Centre. Investigators at the University of
402 Oxford, Oxford, UK, have been supported by the Research and Development Programme of NHSBT,
403 the NHSBT Howard Ostin Trust Fund, and the NIHR Oxford Biomedical Research Centre through the
404 programme grant NIHR-RP-PG-0310-1004. We thank the blood donors who participated in the trial
405 and NHSBT's operational staff.

406 The NEO study is supported by the participating Departments, the Division, and the Board of
407 Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile
408 Area 'Vascular and Regenerative Medicine'. The analyses of metabolites are funded by the VENI
409 grant (ZonMW-VENI Grant 916.14.023) of D.O.M.-K., D.v.H. and R.N. were supported by a grant of
410 the VELUX Stiftung [grant number 1156]. T.O.F. was supported by the King Abdullah Scholarship
411 Program and King Faisal Specialist Hospital & Research Center [No. 1012879283].

412 Conflicts of Interest

413 P.S. is an associate director of applied and statistical genetics at GlaxoSmithKline plc. A.S.B. reports
414 institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and
415 Sanofi. R.L.-G. is a part-time clinical research consultant for Metabolon, Inc. All other co- authors
416 have no conflicts of interest to declare.

417 Acknowledgments and Disclosures

418 The authors of the NEO study thank all participants, all participating general practitioners for inviting
419 eligible participants, all research nurses for data collection, and the NEO study group: Pat van
420 Beelen, Petra Noordijk, and Ingeborg de Jonge for coordination, laboratory, and data management.
421 The NEO study was approved by the medical ethical committee of the Leiden University Medical
422 Centre (LUMC) and all participants provided written informed consent. The INTERVAL study was
423 approved by The National Research Ethics Service (11/EE/0538) and all eligible donors provided a
424 trial consent form before giving a blood donation.

425 Author Contributions

426 T.O.F.- conceptualization, data curation, formal analysis, investigation, methodology, software,
427 visualization, writing-original draft. R.L.-G.- validation, writing – review & editing. P.S. – supervision,
428 conceptualization, project administration, resources, funding acquisition, writing – review & editing -
429 A.S.B – project administration, resources, funding acquisition, writing – review & editing. R.d.M.-
430 project administration, resources, funding acquisition, writing – review & editing. R.N. and D.V.H.-
431 funding acquisition, writing – review & editing. F.R.R.- funding acquisition. A.v.H.V. and K.W.v.D-
432 conceptualization, supervision, writing – review & editing. D.O.M.-K.- conceptualization, supervision,
433 funding acquisition, writing – review & editing.